Amyotrophic Lateral Sclerosis Als Epidemiology Forecast

DelveInsight's ‘Amyotrophic Lateral Sclerosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted Amyotrophic Lateral Sclerosis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Amyotrophic Lateral Sclerosis Disease Understanding and Treatment Algorithm

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a wider group of disorders known as motor neuron diseases caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and muscles throughout the body. Messages from motor neurons in the brain (called upper motor neurons; UMN) are transmitted to motor neurons in the spinal cord and to motor nuclei of the brain (called lower motor neurons; LMN) and from the spinal cord and motor nuclei of the brain to a particular muscle or muscles. ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. Common symptoms include painless, progressive muscle weakness. The first thing a person might notice is tripping more often, or dropping things because of the weakness. Slurred speech, difficulty swallowing, and trouble breathing can occur.

 

Amyotrophic Lateral Sclerosis Diagnosis

ALS is a difficult disease to diagnose. There is no one test or procedure to establish the diagnosis of ALS ultimately. It is through a clinical examination and a series of diagnostic tests, often ruling out other diseases that mimic ALS. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing (with needle EMG), and neuroimaging. Biomarkers can play a crucial role in diagnostic, prognostic, or predictive research studies. They could potentially become important for the stratification of patients and monitoring treatment effects in clinical trials. Genetic testing of the five most prevalent genes found to be mutated in ALS is routinely offered to patients with a positive family history (C9orf72, SOD1, TDP‐43, FUS, and TBK‐1).

Amyotrophic Lateral Sclerosis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by prevalent cases, diagnosed prevalent cases of ALS, gender-specific, site of onset-specific, mutation-specific, type-specific, age-specific prevalence of ALS in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan market from 2019 to 2032.

 

Key Findings

This section provides glimpse of the Amyotrophic Lateral Sclerosis epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  • The total diagnosed prevalent cases of ALS in the 7MM were 52,099 in 2021, growing at a CAGR of 1.02% during the study period (2019–2032).
  • Epidemiology assessed for the condition showed that the US, in 2021, accounted for approximately 20,556 diagnosed prevalent cases of ALS.
  • Among the EU-5 countries in 2021, Germany had the highest diagnosed prevalent cases of ALS with 5,061 cases, followed by UK (4,276) and Italy (4,226). In contrast, Spain had the lowest cases (3,065) in 2021.
  • Japan accounted for 10,742 diagnosed prevalent ALS cases in 2021.
  • In the United States, in 2021, the proportion of male and female cases were 11,902 and 8,654, respectively.
  • As per the analysis, a higher percentage of sporadic ALS was observed in the 7MM compared to familial ALS in 2021.
  • ALS can be divided into C9ORF72, SOD1, FUS, others mutations (TARDBP, OPTN, ANG, etc.), and non-mutated/unidentified mutation based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, FUS, others mutations (TARDBP, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 1,747, 514, 267, 1,743 and  16,284 respectively, in 2021.
  • In 2021, the patients with the spinal site of onset accounted for 12,950 cases, followed by 5,961 cases with the bulbar site of onset, and 1,644 cases with other uncertain regions in the US.
  • Japan accounted for approximately 3,738 cases of 70-79 years of age of ALS in 2021.

Scope of the Report

  • The report covers the descriptive overview of ALS, explaining its causes, signs and symptoms, pathophysiology, and diagnosis
  • Comprehensive insight has been provided into the ALS epidemiology in the 7MM
  • A detailed review of ALS market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global ALS market

Report Highlights

  • In the coming years, ALS market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence ALS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for ALS. Launch of emerging therapies will significantly impact the ALS market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for ALS
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Amyotrophic Lateral Sclerosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • ALS Pipeline Analysis
  • ALS Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Amyotrophic Lateral Sclerosis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • ALS Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Amyotrophic Lateral Sclerosis Report Assessment

  • Disease Understanding
  • Current Diagosis Practices and Guidelines
  • Epidemiology Trends

Key Questions

  • What is the disease risk, burden and regional/ethnic differences of the ALS?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical ALS patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of ALS in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to ALS?
  • Out of all 7MM countries, which country would have the highest prevalent population of ALS during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the ALS market
  • To understand the future market competition in the ALS market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for ALS in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for ALS market
  • To understand the future market competition in the ALS market

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. SWOT Analysis

6. Amyotrophic Lateral Sclerosis (ALS) Market Overview at a Glance

6.1. Market Share (%) Distribution by Therapies in 2022

6.2. Market Share (%) Distribution by Therapies in 2032

7. Disease Background and Overview

7.1. Introduction

7.2. Types of ALS

7.2.1. Sporadic ALS

7.2.2. Genetic or Familial ALS

7.3. Causes

7.3.1. Genetics

7.3.2. Environmental factors

7.4. Risk factors

7.5. Symptoms

7.6. Clinical Features

7.6.1. Clinical presentation

7.6.2. Amyotrophic lateral sclerosis phenotypes

7.6.3. Subtypes of ALS based on relative UMN versus LMN involvement

7.6.4. Subtypes of motor neuron disease based on the regional distribution of involvement

7.6.5. Subtypes of ALS based on additional frontotemporal involvement

7.7. Pathogenesis

7.7.1. Failure of proteostasis

7.7.2. Disturbed RNA metabolism

7.7.3. Cytoskeletal disturbances and axonal transport defects

7.8. Biomarker

7.9. Prediction of prognosis

7.10. Differential Diagnosis

7.11. Diagnosis

8. European Federation of Neurological Societies (EFNS) guidelines on the Clinical Management of ALS (MALS) (2012)

9. American Association of Neurology (AAN) Guidelines for Care and Management of patients with ALS (2009)

10. Management Algorithm for Respiratory Dysfunction in ALS

11. Management guidelines for ALS in Japan, the United States, and Europe.

12. Epidemiology and Patient Population of 7MM

12.1. Key Findings

12.2. Epidemiology Methodology

12.3. Total Prevalent Population of Amyotrophic Lateral Sclerosis (ALS) in the 7MM

12.4. Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis (ALS) in the 7MM

12.5. Assumptions and Rationale

12.6. The United States

12.6.1. Prevalence of Amyotrophic Lateral Sclerosis in the United States

12.6.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the United States

12.6.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

12.6.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

12.6.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

12.6.6. Site of onset of Amyotrophic Lateral Sclerosis in the United States

12.6.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in the United States

12.7. EU5

12.7.1. Prevalence of of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.6. Site of onset of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.7.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5

12.8. Japan

12.8.1. Prevalence of Amyotrophic Lateral Sclerosis in Japan

12.8.2. Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan

12.8.3. Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan

12.8.4. Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan

12.8.5. Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan

12.8.6. Site of onset of Amyotrophic Lateral Sclerosis in Japan

12.8.7. Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan

13. Organizations contributing towards ALS

14. Appendix

15. Bibliography

16. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

Table 1: Summary of Amyotrophic lateral sclerosis (ALS) Market, and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: List of differential diagnosis and clinical overlap with ALS

Table 4: Summary table of ALS and key differentiating factors with each mimic/variant

Table 5: Diagnostic tests for ALS

Table 6: Revised El Escorial Criteria for ALS

Table 7: Total Prevalent Population of ALS in the 7MM (2019–2032)

Table 8: Total Diagnosed Prevalent Population of ALS in the 7MM (2019–2032)

Table 9: Prevalence of ALS in the US (2019–2032)

Table 10: Diagnosed Prevalence of ALS in the US (2019–2032)

Table 11: Gender-specific Distribution of ALS in the US (2019–2032)

Table 12: Mutation-specific Distribution of ALS in the US (2019–2032)

Table 13: Type-specific Distribution of ALS in the US (2019–2032)

Table 14: Site of onset of ALS in the US (2019–2032)

Table 15: Age-specific Distribution of ALS in the US (2019–2032)

Table 16: Prevalence of ALS in EU5 (2019–2032)

Table 17: Diagnosed Prevalence of ALS in EU5 (2019–2032)

Table 18: Gender-specific Distribution of ALS in EU5 (2019–2032)

Table 19: Mutation-specific Distribution of ALS in EU5 (2019–2032)

Table 20: Type-specific Distribution of ALS in EU5 (2019–2032)

Table 21: Site of onset of ALS in EU5 (2019–2032)

Table 22: Age-specific Distribution of ALS in EU5 (2019–2032)

Table 23: Prevalence of ALS in Japan (2019–2032)

Table 24: Diagnosed Prevalence of ALS in Japan (2019–2032)

Table 25: Gender-specific Distribution of ALS in Japan (2019–2032)

Table 26: Mutation-specific Distribution of ALS in Japan (2019–2032

Table 27: Type-specific Distribution of ALS in Japan (2019–2032)

Table 28: Site of onset of ALS in Japan (2019–2032)

Table 29: Age-specific Distribution of ALS in Japan (2019–2032)

Table 30: Organizations contributing toward ALS

List of Figures

Figure 1: Phenotypic presentations of ALS.

Figure 2: Clustering of ALS genes in pathogenic pathways.

Figure 3: Flowchart for the management of respiratory dysfunction in ALS/ motor neuron disease (MND)

Figure 4: Total Prevalent Population of ALS in the 7MM (2019–2032)

Figure 5: Total Diagnosed Prevalent Population of ALS in the 7MM (2019–2032)

Figure 6: Prevalence of ALS in the US (2019–2032)

Figure 7: Diagnosed Prevalence of ALS in the US (2019–2032)

Figure 8: Gender-specific Distribution of ALS in the US (2019–2032)

Figure 9: Mutation-specific Distribution of ALS in the US (2019–2032)

Figure 10: Type-specific Distribution of ALS in the US (2019–2032)

Figure 11: Site of onset of ALS in the US (2019–2032)

Figure 12: Age-specific Distribution of ALS in the US (2019–2032)

Figure 13: Prevalence of ALS in EU5 (2019–2032)

Figure 14: Diagnosed Prevalence of ALS in EU5 (2019–2032)

Figure 15: Gender-specific Distribution of ALS in EU5 (2019–2032)

Figure 16: Mutation-specific Distribution of ALS in EU5 (2019–2032)

Figure 17: Type-specific Distribution of ALS in EU5 (2019–2032)

Figure 18: Site of onset of ALS in EU5 (2019–2032)

Figure 19: Age-specific Distribution of ALS in EU5 (2019–2032)

Figure 20: Prevalence of ALS in Japan (2019–2032)

Figure 21: Diagnosed Prevalence of ALS in Japan (2019–2032)

Figure 22: Gender-specific Distribution of ALS in Japan (2019–2032)

Forward to Friend

Need A Quote